Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-14
2011-06-14
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
07960337
ABSTRACT:
The invention describes a pharmaceutical composition to combat multiple-drug-resistant bacteria in non-ocular infective conditions. Compositions comprising glycopeptides, in particular vancomycin, and cephalosporins, in particular ceftriaxone, are disclosed. Such compositions are found to be useful for parenteral administration for hospitalized patients with serious infections. Specifically, this invention also discloses a pharmaceutical composition further including an excipient such as CVMC agent and is available in dry powder form for reconstitution before injection with a suitable solvent. The pharmaceutical compositions of this invention have been found normally to enhance resistance to precipitation in solutions to be administered parenterally. The invention also gives details of the dosage forms stored in sealed containers to be reconstituted before use. The invention further provides a process to manufacture these compositions and also a method of treating a subject having non-ocular infective conditions due to multi drug resistant bacterium.
REFERENCES:
patent: 4775533 (1988-10-01), Grab
patent: 6087123 (2000-07-01), Wissler et al.
patent: 2003/0186957 (2003-10-01), Blanchflower et al.
patent: 96/22105 (1996-07-01), None
Kazaragis et al., Antimicrobial Agents and Chemotherapy, 1996, vol. 40, pp. 2632-2636.
Desbiolles et al., Antimicrobial Agents and Chemotherapy, 2001, vol. 45, pp. 3328-3333.
Jaing et al., Chang Gung Med. J., 2002, vol. 25, pp. 190-193.
Arias et al., Journal of Chemotherapy, 2001, vol. 13, pp. 535-540.
Climo et al., Anti microbial Agents and Chemotherapy, 1999, pp. 1747-1753.
Huebner et al., S. Afr. Med., 2000, pp. 1116-1121.
Desbiolles et al., Antimicrobial Agents and Chemotherapy, 2001, pp. 3328-3333.
Merck Research Laboratories, “Combinations of antibiotics”, Antibacterial Drugs, 1999, pp. 1101-1102, USA.
Tunkel, et al., “Practice Guidelines for the Treatment of Bacterial Menigitis,” Clinical Infectious Diseases, 2004, pp. 1267-1284, vol. 39, The University of Chicago Press, USA.
Kaplan, et al., “Management of Infections due to Antibiotic ResistantStreptococcus pneumoniae,” Clinical Microbiology Reviews, Oct. 1998, pp. 628-644, vol. 11, No. 4, American Society for Microbiology, USA.
Sharma, et al., “Antibacterial Resistance: Current Problems and Possible Solutions,” Indian Journal of Medical Sciences, 2005, pp. 120-129, vol. 59, No. 3, Medknow Publications, Mumbai, India.
Assadullah, et al., “Emergence of Low Level Vancomycin Resistance in MRSA,” Indian Journal of Medical Microbiology, 2003, pp. 196-198, vol. 21, No. 3, Medknow Publications, Mumbai, India.
Kreiswirth, “Don't Look Now Emerging and Re-Emerging Microbial Diseases: Re-emerging Staphylococci Infections,” located at: http://www.nyas.org/ebriefreps/main.asp?intSubsectionID=1357 (posted Dec. 27, 2004).
Ribes, et al., “Evaluation of Ceftriaxone, Vancomycin and Rifampicin Alone and Combined in an Experimental Model of Meningitis Caused by Highly Cephalosporin-ResistantStreptococcus pneumoniaeATCC 51916,” Journal of Antimicrobial Chemotherapy, 2005, pp. 979-982, vol. 56, No. 5, Oxford University Press, England.
Normark, et al., “Clinical Isolates ofStreptococcus pneumoniaeThat Exhibit Tolerance of Vancomycin,” Clinical Infectious Diseases, 2001, pp. 552-558, vol. 32, The University of Chicago Press, USA.
Novak, et al., “Emergence of Vancomycin Tolerance inStreptococcus pneumoniae,” Nature, 1999, pp. 590-593, vol. 399, Nature Publishing Group, England.
Rodriguez-Cerrato, et al., “Garenoxacin (BMS-284756) and Moxifloxacin in Experimental Meningitis Caused by Vancomycin-Tolerant Pneumococci,” Antimicrobial Agents and Chemotherapy, 2003, pp. 211-215, vol. 47, No. 1, American Society for Microbiology, USA.
Suntur, et al., Rifampicin+Ceftriaxone versus Vancomycin+Ceftriaxone in the Treatment of Penicillin- and Cephalosporin-Resistant Pneumococcal Meningitis in an Experimental Rabbit Model, International Journal of Antimicrobial Agents, 2005, pp. 258-260, vol. 26, Elsevier Science Publishers, Netherlands.
Climo, et al., “Combinations of Vancomycin and Beta-Lactams are Synergistic against Staphylococci with Reduced Susceptibilities to Vancomycin,” Antimicrobial Agents and Chemotherapy, 1999, pp. 1747-1753, vol. 43, No. 7, American Society for Microbiology, USA.
Cizman, et al., “Antimicrobial Resistance of InvasiveStreptococcus pneumoniaein Slovenia, 1993-1995,” Scandinavian Journal of Infectious Disease, 1997, pp. 251-254, vol. 29, Taylor & Francis, Sweden.
Kazragis, et al., “In Vivo Activities of Ceftriaxone and Vancomycin againstBorreliaspp. in the Mouse Brain and Other Sites,” Antimicrobial Agents and Chemotherapy, 1996, pp. 2632-2636, vol. 40, No. 11, American Society for Microbiology, USA.
Salminen, et al., “Ceftriaxone versus Vancomycin Prophylaxis in Cardiovascular Surgery,” Journal of Antimicrobial Chemotherapy, 1999, pp. 287-290, vol. 44, Oxford University Press, England.
Rodriguez, et al., “Tolerance to Vancomycin in Pneumococci: Detection with a Molecular Marker and Assessment of Clinical Impact,” The Journal of Infectious Diseases, 2004, pp. 1481-1487, vol. 190, University of Chicago Press, USA.
Marchese, et al., “The Oxazolidinones as a New Family of Antimicrobial Agent,” Clinical Microbiology & Infection, 2001, pp. 66-74, vol. 7, No. 4, Blackwell Science, France.
Kaplan, “Management of Pneumococcal Meningitis,” Pediatric Infectious Disease Journal, 2002, pp. 589-591, vol. 21, No. 6, Williams & Wilkins, USA.
Jaing, et al., “Successful Treatment of Meningitis Caused by Highly-Penicillin-ResistantStreptococcus mitisin a Leukemic Child,” Chang Gung Medical Journal, 2002, pp. 190-193, vol. 25, Chau-Xiong Zhang, China.
Cottagnoud, et al., “Daptomycin is Highly Efficacious against Penicillin-Resistant and Penicillin- and Quinolone-Resistant Pneumococci in Experimental Meningitis,” Antimicrobial Agents and Chemotherapy, 2004, pp. 3928-3933, vol. 48, No. 10, American Society for Microbiology, USA.
Arias, et al., “Time-Kill Evaluation of Antimicrobial Regimens Against Clinical Isolates of Penicillin-ResistantStreptococcus pneumoniae,” Journal of Chemotherapy, 2001, pp. 535-540, vol. 13, No. 5, E.S.I.F.T. srl, Florence, Italy.
Desbiolles, et al., “Fractional Maximal Effect Method for In Vitro Synergy between Amoxicillin and Ceftriaxone and between Vancomycin and Ceftriaxone againstEnterococcus faecalisand Penicillin-ResistantStreptococcus pneumoniae,” Antimicrobial Agents and Chemotherapy, 2001, pp. 3328-3333, vol. 45, No. 12, American Society for Microbiology, USA.
Huebner, et al., “Prevalence of Nasopharyngeal Antibiotic-Resistant Pneumococcal Carriage in Children Attending Private Paediatric Practices in Johannesburg,” South African Medical Journal, 2000, pp. 1116-1121, vol. 90, No. 11, South African Medical Association, South Africa.
Roos, “Bacterial Meningitis,” Current Treatment Options in Neurology, 1999, pp. 147-156, vol. 1, Current Science, USA.
P. Cottagnoud et al., “Cefepime is efficacious against penicillin- and quinolone-resistant pneumococci in experimental meningitis,” Journal of Antimicrobial Chemotherapy, 2002, pp. 327-330, vol. 49, No. 2, Oxford University Press, England.
A. Marchese et al., “In Vitro Activity of Thiamphenicol against Methicillin-resistant (MRSA) and Vancomycin-intermediate (VISA)Staphylococcus aureusStrains,” Abstract of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Sep. 17-20, 2000; vol. 40: No. 167. American Society for Microbiology, U.S.
H. Wang et al., “Antibiotic Susceptibility Patterns ofStreptococcus pneumoniaein China and Comparison of MICs by Agar Dilution and E-Test Methods,” Antimicrobial Agents and Chemotherapy, Oct. 1998, pp. 2633-2636, vol. 42, No. 10,
David Bradin Hultquist IP
Tate Christopher R.
Teller Roy
Venues Remedies Limited
LandOfFree
Parenteral combination therapy for infective conditions with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Parenteral combination therapy for infective conditions with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Parenteral combination therapy for infective conditions with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2700934